180 related articles for article (PubMed ID: 21739727)
1. Active surveillance monitoring more stringent in updated NCCN Guidelines for prostate cancer.
J Natl Compr Canc Netw; 2011 May; 9(5):xxxvii-xlii. PubMed ID: 21739727
[No Abstract] [Full Text] [Related]
2. Critical review: is watchful waiting a viable management option for older men with prostate cancer?
Bailey DE; Wallace M
Am J Mens Health; 2007 Mar; 1(1):18-28. PubMed ID: 19482780
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance for early-stage prostate cancer.
Lancet; 2014 Jan; 383(9913):188. PubMed ID: 24439724
[No Abstract] [Full Text] [Related]
4. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Bartoletti R; Cai T
Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
[No Abstract] [Full Text] [Related]
5. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria.
Miocinovic R; Jones JS; Pujara AC; Klein EA; Stephenson AJ
Urology; 2011 Apr; 77(4):980-4. PubMed ID: 21256549
[TBL] [Abstract][Full Text] [Related]
6. Update of the NCCN guidelines for treatment of prostate cancer.
Millikan R; Logothetis C
Oncology (Williston Park); 1997 Nov; 11(11A):180-93. PubMed ID: 9430189
[No Abstract] [Full Text] [Related]
7. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
Albertsen P
Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
[No Abstract] [Full Text] [Related]
8. Feasibility of using guidelines to choose treatment for prostate cancer.
Mohan R; Beydoun H; Davis J; Lance R; Schellhammer P
Can J Urol; 2010 Feb; 17(1):4975-84. PubMed ID: 20156376
[TBL] [Abstract][Full Text] [Related]
9. [Active surveillance of prostatic cancer].
Vasarainen H; Ruutu M; Rannikko A
Duodecim; 2011; 127(6):593-9. PubMed ID: 21528523
[TBL] [Abstract][Full Text] [Related]
10. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer.
Gorin MA; Soloway CT; Eldefrawy A; Soloway MS
Urology; 2011 Mar; 77(3):588-91. PubMed ID: 21215429
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Gallina A
Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
[No Abstract] [Full Text] [Related]
12. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Yossepowitch O
Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
[No Abstract] [Full Text] [Related]
13. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.
Soloway MS; Soloway CT; Eldefrawy A; Acosta K; Kava B; Manoharan M
Eur Urol; 2010 Dec; 58(6):831-5. PubMed ID: 20800964
[TBL] [Abstract][Full Text] [Related]
14. NCCN Practice Guidelines for Prostate Cancer.
Bahnson RR; Hanks GE; Huben RP; Kantoff P; Kozlowski JM; Kuettel M; Lange PH; Logothetis C; Pow-Sang JM; Roach M; Sandler H; Scardino PT; Taylor RJ; Urban DA; Walsh PC; Wilson TG;
Oncology (Williston Park); 2000 Nov; 14(11A):111-9. PubMed ID: 11195405
[TBL] [Abstract][Full Text] [Related]
15. Editorial comment.
Carroll PR; Whitson JM
Urology; 2011 Apr; 77(4):984-5. PubMed ID: 21477729
[No Abstract] [Full Text] [Related]
16. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Ladjevardi S; Sandblom G; Berglund A; Varenhorst E
Eur Urol; 2010 Apr; 57(4):631-8. PubMed ID: 19299069
[TBL] [Abstract][Full Text] [Related]
17. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.
Cooperberg MR; Lin DW; Morgan TM; Chapin BF; Chen RC; Eggener SE
J Urol; 2022 Feb; 207(2):262-264. PubMed ID: 34775795
[No Abstract] [Full Text] [Related]
18. [Watchful waiting in incidental adenocarcinoma of the prostate].
Morán Pascual E; Dicapua Sacoto C; Trassierra Villa M; Pontones Moreno JL; Ruiz Cerdá JL; Jiménez Cruz JF
Actas Urol Esp; 2010 Nov; 34(10):854-9. PubMed ID: 21159280
[TBL] [Abstract][Full Text] [Related]
19. [Active surveillance in prostate cancer. Introduction].
Briones JR
Arch Esp Urol; 2014 Jun; 67(5):367-8. PubMed ID: 25039087
[No Abstract] [Full Text] [Related]
20. The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer.
Anai S; Nakamura K; Chang MN; Pendleton J; Yacoub S; Rosser CJ
J Health Care Poor Underserved; 2008 Feb; 19(1):164-70. PubMed ID: 18263992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
